Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antidepressant Drugs: MAOIs and Other Agents01:23

Antidepressant Drugs: MAOIs and Other Agents

1.1K
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
1.1K
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs01:28

Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs

1.9K
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
1.9K
Antidepressant Drugs: Overview01:25

Antidepressant Drugs: Overview

1.9K
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
1.9K
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

775
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
775
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

1.2K
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.2K
Treatment Strategies for Psychological Disorders01:24

Treatment Strategies for Psychological Disorders

876
Treatment approaches for psychological disorders fall into three main categories: psychological, biological, and sociocultural. Each approach targets different aspects of mental health, requiring varying levels of education and training.
Psychological therapies focus on modifying emotions, thoughts, and behaviors through talking, interpreting, listening, rewarding, challenging, and modeling. Clinical psychologists, counselors, and social workers commonly practice psychotherapy. Clinical...
876

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Empirical limitations of current low-intensity focused ultrasound simulation platforms.

Brain stimulation·2026
Same author

Anhedonia in patients with major depressive disorder (MDD): State-of-the-art consensus review.

Psychiatry research·2026
Same author

Simulated Reasoning and Self-Verification for Psychiatric Diagnosis in Generalist Large Language Models: Comparative Evaluation.

JMIR AI·2026
Same author

Targeted Connectomic Neuromodulation of the Orbitofrontal Cortex To Treat Obsessive-Compulsive Disorder.

medRxiv : the preprint server for health sciences·2026
Same author

Design and Recruitment for the Comparative Effectiveness of Zolpidem/Trazodone and Cognitive Behavioral Therapy for Insomnia (COZI) Study in Rural Adults.

Behavioral sleep medicine·2026
Same author

Scalable biomarkers of Parkinson's disease: insights from mobile EEG in Peru.

Scientific reports·2026

Related Experiment Video

Updated: Mar 14, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.8K

Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale.

Jacob P R Jacobsen1, Andrew D Krystal2, K Ranga R Krishnan3

  • 1Department of Cell Biology, Duke University, Durham, NC 27710, USA.

Trends in Pharmacological Sciences
|October 4, 2016
PubMed
Summary
This summary is machine-generated.

Slow-release 5-hydroxytryptophan (5-HTP SR) may offer a novel treatment for treatment-resistant depression (TRD). This approach enhances serotonin levels beyond standard antidepressants, addressing a significant unmet clinical need.

Keywords:
5-hydroxytryptophanAntidepressantdepressiontreatment-resistant depression

More Related Videos

Radiosynthesis of 1-2-[18F]Fluoroethyl-L-Tryptophan using a One-pot, Two-step Protocol
08:33

Radiosynthesis of 1-2-[18F]Fluoroethyl-L-Tryptophan using a One-pot, Two-step Protocol

Published on: September 21, 2021

3.7K
Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet
07:05

Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet

Published on: January 3, 2017

9.4K

Related Experiment Videos

Last Updated: Mar 14, 2026

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.8K
Radiosynthesis of 1-2-[18F]Fluoroethyl-L-Tryptophan using a One-pot, Two-step Protocol
08:33

Radiosynthesis of 1-2-[18F]Fluoroethyl-L-Tryptophan using a One-pot, Two-step Protocol

Published on: September 21, 2021

3.7K
Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet
07:05

Behavioral Disturbances: An Innovative Approach to Monitor the Modulatory Effects of a Nutraceutical Diet

Published on: January 3, 2017

9.4K

Area of Science:

  • Neuroscience
  • Pharmacology
  • Psychiatry

Background:

  • Selective serotonin reuptake inhibitors (SSRIs) increase extracellular serotonin (5-HTExt) but are ineffective for many depression patients.
  • Treatment-resistant depression (TRD) represents a significant challenge in mental healthcare.
  • Elevating 5-HTExt beyond SSRI effects shows promise for TRD treatment.

Purpose of the Study:

  • To review the evidence for 5-hydroxytryptophan (5-HTP) as an adjunctive treatment for TRD.
  • To explore the potential of slow-release (SR) 5-HTP formulations to overcome pharmacokinetic limitations.

Main Methods:

  • Review of preclinical animal studies on 5-HTP pharmacokinetics and efficacy.
  • Analysis of clinical data on adjunctive 5-HTP administration in depression.
  • Evaluation of the predicted benefits of slow-release (SR) 5-HTP formulations.

Main Results:

  • Adjunctive 5-HTP can safely increase 5-HTExt beyond SERT inhibitor levels in humans.
  • Standard 5-HTP has poor pharmacokinetics, limiting its clinical viability.
  • Animal studies suggest SR 5-HTP overcomes pharmacokinetic issues, enhancing efficacy.

Conclusions:

  • Slow-release 5-HTP (5-HTP SR) holds significant potential as a novel therapeutic strategy for TRD.
  • 5-HTP SR could represent a clinically viable advancement over existing depression treatments.
  • Further clinical investigation of 5-HTP SR for TRD is warranted.